Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) FCF Yield % : -0.69 (As of May. 15, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Merrimack Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-1.52 Mil, and Market Cap is $219.72 Mil. Therefore, Merrimack Pharmaceuticals's FCF Yield % for today is -0.69%.

The historical rank and industry rank for Merrimack Pharmaceuticals's FCF Yield % or its related term are showing as below:

MACK' s FCF Yield % Range Over the Past 10 Years
Min: -708.86 Med: -95.14 Max: -0.69
Current: -0.69

During the past 13 years, the highest FCF Yield % of Merrimack Pharmaceuticals was -0.69%. The lowest was -708.86%. And the median was -95.14%.

MACK's FCF Yield % is ranked better than
83.72% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs MACK: -0.69

Merrimack Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Merrimack Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Merrimack Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals FCF Yield % Chart

Merrimack Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-74.43

-5.02

-0.42

-1.07

-0.79

Merrimack Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-0.45	-0.81	-1.52	-0.46	-0.61

Competitive Comparison of Merrimack Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Merrimack Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merrimack Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's FCF Yield % falls into.

Merrimack Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Merrimack Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1.522	/	192.44691
	=	-0.79%

Merrimack Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.295	*	4	/	192.44691
	=	-0.61%

Merrimack Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Merrimack Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.merrimack.com

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Executives

Eric Andersen	director, other: See Remarks	1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker	director, officer: President	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy	director, other: See Remarks	60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic	director	2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p.	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc	other: See Remarks	5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc.	10 percent owner, other: See Explanation of Responses	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107